Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

163 public trials 32 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Conditions
Agammaglobulinemia, Antibody Deficiency, Blood Protein Disorders, +11 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

NCT03907241

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Octapharma Research Site Irvine, California, United States
  • Octapharma Research Site San Diego, California, United States
  • Octapharma Research Site Centennial, Colorado, United States
  • Octapharma Research Site Papillion, Nebraska, United States
View Trial Details
Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02806986

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Wesley Medical Research Auchenflower, Australia
  • Royal Melbourne Hospital Parkville, Australia
  • University Hospital Hradec Králové, Czechia
  • CHU de Montpellier Montpellier, France
View all 23 locations
View Trial Details
Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Clinical Research Center of Alabama Birmingham, Alabama, United States
  • Research Solutions of Arizona Litchfield Park, Arizona, United States
  • University of Southern Florida St. Petersburg, Florida, United States
  • Georgia Pollens Clinical Research Centers Albany, Georgia, United States
View Trial Details
Completed

Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

NCT03988426

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • The State Research Center, Institute of Immunology of the Federal Medical-Biological Agency Moscow, Russia
  • Federal Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health and Social Development of the Russian Federation Moscow, Russia
  • State Medical University Rostov-on-Don, Russia
  • Pasteur Institute Saint Petersburg, Russia
View Trial Details
Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02604810

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • AIRE Medical of Los Angeles Santa Monica, California, United States
  • National Jewish Health Denver, Colorado, United States
  • University of Miami - Batchelor Children's Research Institute Miami, Florida, United States
View all 25 locations
View Trial Details
Completed

Primary Immunodeficiency in Kuwait

NCT03618147

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Pediatric Deprtmemt, Alsabah hospital Kuwait City, Kuwait
View Trial Details
Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

NCT02176239

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare) Newport Beach, California, United States
  • IMMUNEOe International Research Centers Centennial, Colorado, United States
  • Atlanta ENT Atlanta, Georgia, United States
  • AxelaCare Health Solutions, LLC Lenexa, Kansas, United States
View Trial Details

Related conditions